Investigating how certain immune cells affect cancer growth
Official title: Follicular Regulatory T-cells Promote Cancer
Funded at University of Alabama at Birmingham · NIH-10993082 · Data updated 2026-11-12
This study is looking at how certain immune cells called follicular regulatory T-cells affect cancer growth, especially in melanoma, to find new ways to help the body fight tumors better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $384,562 |
| NIH project number | 5R01CA276190-03 |
| Project ID | NIH-10993082 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancers such as melanoma who are seeking innovative treatment options.
✕Less likely to help
Patients with non-cancerous conditions or those whose cancers are not influenced by immune mechanisms may not benefit from this research.
What this research studies
This research focuses on understanding the role of follicular regulatory T-cells in cancer progression. By examining how these immune cells interact with other immune components, the study aims to uncover mechanisms that tumors use to evade the immune system. The researchers will analyze the behavior of these cells in various cancers, including melanoma, to identify potential therapeutic targets. This could lead to new strategies for enhancing anti-tumor immunity and improving cancer treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have gone: Previous research has shown promising results in targeting immune cells to improve cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Leavenworth, Jianmei Wu — University of Alabama at Birmingham
- Study coordinator: Leavenworth, Jianmei Wu
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Exploring how Down syndrome affects optic nerve health in kids
A study using a mouse model to understand why optic nerve problems are common in children with Down syndrome and how to prevent them.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.